<DOC>
	<DOCNO>NCT02718937</DOCNO>
	<brief_summary>The primary purpose study evaluate antiviral activity oral BTA-C585 compare placebo healthy volunteer intranasal challenge RSV-A Memphis 37b virus .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics BTA-C585 RSV Viral Challenge Study</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Healthy male female 2 . Between 18 50 year old 3 . Body mass index 18 30 kg/m2 1 . Acute chronic medical illness 2 . Abnormal lung function Positive HIV , Hepatitis B C 3 . Any significant abnormality nose nasopharynx</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Viral disease</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Paramyxoviridae infection</keyword>
	<keyword>RSV</keyword>
	<keyword>Aviragen Therapeutics , Inc .</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>